Glucose-lowering medication in type 2 diabetes: overall approach.

Slides:

Advertisements

Similar presentations

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

Advertisements

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Copyright © 2015 by the American Osteopathic Association.

James Thrasher, MD The American Journal of Medicine

Copyright © 2015 by the American Osteopathic Association.

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Copyright © 2015 by the American Osteopathic Association.

Leveraging Registry Data: Uncovering Gaps and Discovering Opportunities to Improve How We Manage CVD Risk in Patients with T2DM Suzanne V. Arnold, MD,

Copyright © 2015 by the American Osteopathic Association.

Adherence to and persistence with oral antidiabetic medication were evaluated in a sample of 238,372 patients with type 2 diabetes initiating a dipeptidyl.

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

Stuart A. Ross, MB CHB, FRACP, FRCP(C)

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

Updates on CVOT Data and Clinical Comparisons That Matter

Global Projections for Diabetes:

Updates on Outcomes for Novel T2D Therapies

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

SGLT2 Inhibitors and CV Outcomes

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use David M. Kendall, MD, Robert M. Cuddihy, MD,

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Clinical Application of New CV Outcomes Data

A Deep Dive Into CVOTs.

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

James Thrasher, MD The American Journal of Medicine

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Case Study Role of DPP-4 Inhibitors

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic Therapy

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Figure 2 Clinical vignette and putative causal relationships

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Patient Selection for Modern T2D Agents

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Figure 1 Sites of action of glucose-lowering agents

Improving Overall Health

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management G. B. John Mancini, MD, Alice.

ADA/EASD general recommendations for type 2 diabetes management (1).

Results of sensitivity analyses.

Glycaemic management of type 2 diabetes

Enrollment of patients.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Completed and ongoing CVOTs (6–14,39,44–58)

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

What's New in Oral Combination Therapy for Type 2 Diabetes?

This figure illustrates the importance of heart failure consideration in primary endpoint trials with hypoglycemic agents. This figure illustrates the.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Comorbid conditions and concomitant medications.

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Patient disposition and study protocol.

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Presentation transcript:

Glucose-lowering medication in type 2 diabetes: overall approach. Glucose-lowering medication in type 2 diabetes: overall approach. For appropriate context, see Figure 1. CV, cardiovascular; CVOTs, cardiovascular outcomes trials; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, GLP-1 receptor agonist; HbA1c, glycated hemoglobin; HF, heart failure; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. Adapted from Davies MJ, D’Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701. American Diabetes Association Clin Diabetes 2019;37:11-34 ©2019 by American Diabetes Association